Core Viewpoint - The stock of Giant Bio (02367) experienced a significant decline of 15% during trading, with a current drop of 11.8%, trading at HKD 54.2, and a transaction volume of HKD 1.716 billion [1] Group 1: Company Response and Actions - Huaxi Bio has officially responded to the controversy surrounding Dr. Hao Yu, stating that it has collaborated with multiple third-party testing organizations to assess related products, revealing that the recombinant collagen protein content did not meet standards in several test results [1] - Huaxi Bio has submitted dozens of test reports to the National Medical Products Administration [1] - Giant Bio quickly denied the allegations, asserting that its product complies with standards and that internal testing results exceed 0.1% [1] Group 2: Controversy and Public Reactions - On May 24, beauty blogger Dr. Hao Yu released a test report claiming that the actual recombinant collagen protein content in Giant Bio's "Collagen Stick" was only 0.0177%, significantly lower than advertised, and that the key amino acid glycine was "not detected," raising concerns of false advertising [1] - Following the initial claims, Giant Bio received an apology from the testing organization used by Dr. Hao Yu, stating that it had "never authorized Dr. Hao to use the report" [1] - On June 23, Giant Bio acknowledged that its "existing quality standards, testing methods, and labeling have gradually shown limitations in certain aspects" [1]
港股异动 | 巨子生物(02367)盘中重挫15% 可复美成分之争再起波澜 华熙生物称已提交数十份检测报告